Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
12 October 2023 - 11:00PM
Business Wire
Novocure (NASDAQ: NVCR) today announced it has entered into an
agreement with Stanford University to establish the Stanford School
of Medicine Tumor Treating Fields (TTFields) Research Program. The
program is intended to support both preclinical studies and
clinical trials with TTFields, electric fields that exert physical
forces to kill cancer cells via a variety of mechanisms.
“We look forward to collaborating with Stanford Medicine to
establish a research framework for preclinical and clinical
development of TTFields,” said Moshe Giladi, Ph.D., Novocure’s
Chief Science Officer. “Together, we will enable new discoveries
into the mechanisms and treatment possibilities of TTFields,
including new indications and uses of TTFields along with other
therapies. We will pursue our mission to extend survival in some of
the most aggressive forms of cancer while enhancing the education
and scholarship of future clinicians and scientists.”
To enable novel preclinical research, Novocure will provide
Stanford Medicine investigators with its portfolio of proprietary
inovitro™, inovitro Live™ and inovivo™ TTFields preclinical systems
which allows for exploring a vast range of research questions,
starting from the fundamental physical mode of action all the way
to most complex systemic biological outcomes. In addition, Novocure
will provide devices for clinical studies.
At present, Stanford Medicine is a site for four clinical
studies of TTFields therapy. This includes TRIDENT, a
Novocure-sponsored multi-center study of TTFields therapy given
concomitantly with radiation therapy and temozolomide in newly
diagnosed glioblastoma (GBM) patients, in which Stanford University
Cancer Institute is one of 132 participating study centers.
Investigator-sponsored trials at Stanford include multiple
investigational uses, including a study of TTFields therapy for
children with high-grade glioma or ependymoma and TTFields therapy
for children with diffuse intrinsic pontine glioma, a study of
TTFields therapy with hypofractionated chemoradiotherapy in newly
diagnosed GBM, and a study of TTFields therapy with bevacizumab in
treating patients with recurrent or progressive Grade 2 or 3
meningioma.
In addition, Stanford is home to a preclinical study of the
efficacy of TTFields in medulloblastoma.
“With this initiative, we will establish a research
infrastructure for preclinical and clinical development of TTFields
and of potential new indications and combination therapies using
TTFields,” said Michael Lim, M.D., Chair of the Department of
Neurosurgery at Stanford Medicine. “We hope that this collaboration
will educate, bring together, and inspire a diverse group of
leaders in medicine and science who will help further our mission
to deliver outstanding patient-centered care and improve human
health through discovery, innovation, and education.”
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) are electric fields that exert
physical forces to kill cancer cells via a variety of mechanisms.
TTFields do not significantly affect healthy cells because they
have different properties (including division rate, morphology, and
electrical properties) than cancer cells. The multiple, distinct
mechanisms of TTFields therapy work together to selectively target
and kill cancer cells. Due to its multimechanistic actions,
TTFields therapy can be added to cancer treatment modalities in
approved indications and demonstrates enhanced effects across solid
tumor types when used with chemotherapy, radiotherapy, immune
checkpoint inhibition, or targeted therapies in preclinical models.
TTFields therapy provides clinical versatility that has the
potential to help address treatment challenges across a range of
solid tumors. To learn more about Tumor Treating Fields therapy and
its multifaceted effect on cancer cells, visit
tumortreatingfields.com.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical studies
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical study progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions as well as issues arising from the COVID-19
pandemic and other more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2023, and subsequent flings with the U.S.
Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements. Furthermore, Novocure does
not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak
only as of the date hereof. The Private Securities Litigation
Reform Act of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231012581601/en/
Investors: Ingrid Goldberg investorinfo@novocure.com
610-723-7427
Media: Leigh Labrie media@novocure.com 610-723-7428
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2024 to May 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From May 2023 to May 2024